Cyclerion Therapeutics, Inc.
CYCN
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, anā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.45
Price-1.36%
-$0.02
1Y
Price
Market Cap
$4.839m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-111.5%
EBITDA Margin-111.5%
Net Profit Margin-30.2%
Free Cash Flow MarginRevenue
$2.855m
+42.8%
1y CAGR-19.1%
3y CAGR-37.1%
5y CAGREarnings
-$2.199m
+28.1%
1y CAGR+52.7%
3y CAGR+43.2%
5y CAGREPS
-$0.76
+37.2%
1y CAGR+59.7%
3y CAGR+50.7%
5y CAGRBook Value
$9.538m
$10.415m
Assets$877k
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$1.375m
+68.3%
1y CAGR+65.2%
3y CAGR+46.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company